163 related articles for article (PubMed ID: 27852977)
21. [Methylation status of FHIT gene in plasma and expression of FHIT gene in cancer tissue of cervical cancer patients].
Ren CC; Miao XH; Yang B; Zhao L; Sun R; Song WQ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Oct; 23(5):565-7. PubMed ID: 17029211
[TBL] [Abstract][Full Text] [Related]
22. Molecular and epigenetic analysis of the fragile histidine triad tumour suppressor gene in equine sarcoids.
Strazzullo M; Corteggio A; Altamura G; Francioso R; Roperto F; D'Esposito M; Borzacchiello G
BMC Vet Res; 2012 Mar; 8():30. PubMed ID: 22424615
[TBL] [Abstract][Full Text] [Related]
23. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
[TBL] [Abstract][Full Text] [Related]
24. The tumor suppressor Fhit acts as a repressor of beta-catenin transcriptional activity.
Weiske J; Albring KF; Huber O
Proc Natl Acad Sci U S A; 2007 Dec; 104(51):20344-9. PubMed ID: 18077326
[TBL] [Abstract][Full Text] [Related]
25. Restoration of fragile histidine triad (FHIT) expression inhibits cell growth and induces apoptosis in cutaneous T-cell lymphoma cell line.
Song X; Tian Z; Wang S; Peng Z; Feng J
Cancer Invest; 2010 Dec; 28(10):1019-23. PubMed ID: 20690795
[TBL] [Abstract][Full Text] [Related]
26. A mouse model of the fragile gene FHIT: From carcinogenesis to gene therapy and cancer prevention.
Zanesi N; Pekarsky Y; Croce CM
Mutat Res; 2005 Dec; 591(1-2):103-9. PubMed ID: 16085127
[TBL] [Abstract][Full Text] [Related]
27. Effect of exogenous E2F-1 on the expression of common chromosome fragile site genes, FHIT and WWOX.
Ishii H; Mimori K; Vecchione A; Sutheesophon K; Fujiwara T; Mori M; Furukawa Y
Biochem Biophys Res Commun; 2004 Apr; 316(4):1088-93. PubMed ID: 15044096
[TBL] [Abstract][Full Text] [Related]
28. The significance of fragile histidine triad protein as a molecular prognostic marker of bladder urothelial carcinoma.
Zhang CT; Lu R; Lin YL; Liu RL; Zhang ZH; Yang K; Dang RF; Zhang HT; Shen YG; Kong PZ; Ren HL; Li XL; Quan W; Xu Y
J Int Med Res; 2012; 40(2):507-16. PubMed ID: 22613411
[TBL] [Abstract][Full Text] [Related]
29. Aberrant FHIT protein expression in classical Hodgkin's lymphoma: a potential marker.
Zhao P; Lam AK; Lu YL; Zhong M; Chen LH; Pu XL
Pathology; 2006 Oct; 38(5):399-402. PubMed ID: 17008276
[TBL] [Abstract][Full Text] [Related]
30. Decreased fragile histidine triad expression in colorectal cancer and its association with apoptosis inhibition.
Cao J; Chen XP; Li WL; Xia J; Du H; Tang WB; Wang H; Chen XW; Xiao HQ; Li YY
World J Gastroenterol; 2007 Feb; 13(7):1018-26. PubMed ID: 17373735
[TBL] [Abstract][Full Text] [Related]
31. FHIT
Da Silva J; Jouida A; Ancel J; Dalstein V; Routhier J; Delepine G; Cutrona J; Jonquet A; Dewolf M; Birembaut P; Deslée G; Polette M; Nawrocki-Raby B
J Pathol; 2020 Jun; 251(2):187-199. PubMed ID: 32237123
[TBL] [Abstract][Full Text] [Related]
32. [Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas].
Hong FZ; Wang B; Li HM; Liew CT
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):257-61. PubMed ID: 16181544
[TBL] [Abstract][Full Text] [Related]
33. The mechanism of action of the fragile histidine triad, Fhit: isolation of a covalent adenylyl enzyme and chemical rescue of H96G-Fhit.
Huang K; Arabshahi A; Wei Y; Frey PA
Biochemistry; 2004 Jun; 43(23):7637-42. PubMed ID: 15182206
[TBL] [Abstract][Full Text] [Related]
34. The Fragile Histidine Triad gene and breast cancer.
Yang Q; Yoshimura G; Sakurai T; Kakudo K
Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
[TBL] [Abstract][Full Text] [Related]
35. Chemical Proteomics of the Tumor Suppressor Fhit Covalently Bound to the Cofactor Ap
Herzog D; Jansen J; Mißun M; Diederichs K; Stengel F; Marx A
J Am Chem Soc; 2022 May; 144(19):8613-8623. PubMed ID: 35522782
[TBL] [Abstract][Full Text] [Related]
36. The Clinical Relevance of Fragile Histidine Triad Protein (FHIT) in Patients with Bladder Cancer.
Liu XP; Yin XH; Yan XH; Zeng XT; Wang XH
Med Sci Monit; 2018 May; 24():3113-3118. PubMed ID: 29752880
[TBL] [Abstract][Full Text] [Related]
37. [Expression of FHIT and MDM2 in oral submucous fibrosis and canceration tissues].
Yin X; Wen C; Han Y; Gao Y; Tang Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Jun; 35(6):572-5. PubMed ID: 20622329
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the role of Fhit in suppression of DNA damage.
Saldivar JC; Bene J; Hosseini SA; Miuma S; Horton S; Heerema NA; Huebner K
Adv Biol Regul; 2013 Jan; 53(1):77-85. PubMed ID: 23102829
[TBL] [Abstract][Full Text] [Related]
39. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
